COMMUNIQUÉS West-GlobeNewswire

Scilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
06/07/2026
PALO ALTO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non- [...]
Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy
06/07/2026
Key Points Immuron Engages Pullan Consulting to Advance IMM-529 Partnering Strategy Immuron is seeking a partner to support clinical development through regulatory approval and commercialization Immuron has U.S. Food [...]
NovMetaPharma and the FSHD Canada Foundation Establish Collaboration to Advance Cyclo-Z, a First-in-Class Oral Muscle-Preserving Therapy, into Facioscapulohumeral Muscular Dystrophy
06/07/2026
Disease-foundation-funded program extends NovMetaPharma’s muscle-preservation platform into a serious neuromuscular disease with no approved disease-modifying treatment; collaboration provides non-dilutive capital to [...]
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026
06/07/2026
Latest findings on neflamapimod to be featured in presentations demonstrating its impact on dementia with Lewy bodies (DLB) disease progression, biomarkers of neurodegeneration, and basal forebrain atrophy, as well as [...]
Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease
06/07/2026
Successful Type B RDEP Meeting confirms FDA alignment on pivotal Phase 3 study design FDA indicates Opus Genetics may submit a BLA based on 6-month efficacy data, with 12-month durability data provided during review [...]
AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder
06/07/2026
156 patients randomized in multi-center, double-blind, placebo-controlled Phase 2b Elumina trial; topline data anticipated in Q4 2026 (ClinicalTrials.gov: NCT06524830 ) AtaiBeckley plans to advance VLS-01 into major [...]
Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
06/07/2026
U.S. Department of Health and Human Services (HHS) announced advanced Notice of Termination of the COVID-19 EUA declaration, effective June 29, 2027 Consequently, Invivyd received from the U.S. Food and Drug [...]
Astex Announces Exclusive Research Collaboration and License Agreement with Genentech for Breast Cancer Therapy Program
06/07/2026
Collaboration leverages Astex’s industry-leading, fragment-based drug discovery capability to target a key cell-cycle-dependent regulator in breast cancer Astex to receive an upfront and potential milestone payments, [...]
Virbac : Declaration of the number of shares and voting rights 06/2026
06/07/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Virbac : Déclaration d'actions et de droits de vote 06/2026
06/07/2026
DÉCLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
06/07/2026
COPENHAGEN, Denmark, July 6, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on June 2, 2026, under which the Company will repurchase shares for an amount up to [...]
Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients
06/07/2026
Adds potential first-in-class, N-myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform, designed to address resistance to current payloads Strengthens the Novartis oncology pipeline with [...]
REPRONOVO ANNOUNCES FIRST PARTICIPANT DOSED IN EU PHASE 2 TRIAL OF RPN-002 FOR EMBRYO IMPLANTATION
06/07/2026
Lausanne, Switzerland and Copenhagen, Denmark, July 06, 2026 (GLOBE NEWSWIRE) -- REPRONOVO ANNOUNCES FIRST PARTICIPANT DOSED IN EU PHASE 2 TRIAL OF RPN-002 FOR EMBRYO IMPLANTATION RPN-002 is an orally administered [...]
Myricx Bio to be Acquired by Novartis to Advance Next-Generation ADC Payloads for Oncology with Novel NMTi Platform
06/07/2026
Potential first-in-class N-myristoyltransferase inhibitor (NMTi) ADC payload with a differentiated mechanism of action Combines oncology expertise of Novartis with Myricx Bio’s novel ADC assets and platform having broad [...]
InnoCare Announces First Patient Dosed in Clinical Trial of Novel CDH17 targeted ADC ICP-B208 in China
06/07/2026
BEIJING, July 05, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first [...]
Mark Leeds, D.O. PA Launches FloridaTaper.com, a Free Educational Resource on Benzodiazepine Tapering, Withdrawal, and BIND
04/07/2026
The new website from Mark Leeds, D.O. PA offers more than 60 physician-written articles, with new articles published daily, for patients, families, and clinicians navigating slow benzodiazepine dose reductions. Fort [...]
Transactions of Managers and Closely Associated Persons
03/07/2026
Attached are copies of two filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the pledging of (i) 88,940,619 [...]
Teladoc Health Announces Employee Inducement Award under NYSE Rule 303A.08
03/07/2026
NEW YORK, July 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today announced that it issued an inducement award to a new employee. Effective July 1, 2026, in [...]
Court Approval of a Restructuring Transaction Allowing Continuation of Uninterrupted Operations
03/07/2026
MONTREAL, July 03, 2026 (GLOBE NEWSWIRE) -- PREMIER HEALTH OF AMERICA INC. (TSX-V: PHA) (“ Premier Health” or the “Company” ) announces that, in connection with the proceedings initiated on June 23, 2026 by the Royal [...]

Pages